IL33 and neoplasm: The addition of the mTOR inhibitor rapamycin reduced IL33-induced LD formation and DGAT1/2 and PPARG expression, as well as the survival ability, proliferation ability, and ability to promote tumor cell proliferation of teHDNs (Fig. 6H-N).